CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Atropine and Dexamethasonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05560542
NCT05560542N/ACompleted

Prophylactic Efficacy and Safety of Intrathecal Dexamethasone, Atropine or Their Combination on Morphine Induced Post-operative Nausea and Vomiting on Patients Undergoing Caesarean Section With Spinal Anaesthesia

Assiut University·interventional·Posted Sep 29, 2022·Updated Jan 21, 2026

In Brief

A clinical study evaluating Atropine and Dexamethasone for Morphine Adverse Reaction. Completed, enrolled 150 participants across 1 site.

Detailed Summary

Pain is a major problem during the postoperative period and can be considered as a challenge for the anesthesiologist. Low dose intrathecal morphine is proven efficient as a mode to reduce postoperative pain. Morphine has many complications like post-operative nausea and vomiting (PONV). the investigators will investigate the utility of intrathecal (IT) atropine and dexamethasone for prevention of morphine induced PONV as a primary outcome in parturient undergoing CS under spinal bupivacaine anesthesia plus morphine sulfate as an adjuvant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedSep 29, 2022
Enrollment StartOct 1, 2022
Primary CompletionMar 1, 2025
Study CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.8 years ago

Interventions

Atropine and Dexamethasonedrug

Intrathecal dexamethasone, atropine or their combination.